Microbial metabolite-guided CAR T cell engineering enhances anti-tumor immunity via epigenetic-metabolic crosstalk

Sarah Staudt,Fabian Nikolka,Markus Perl,Julia Franz,Noemie Leblay,Xiaoli-Kat Yuan,Linda Warmuth,Matthias A Fantes,Aiste Skorpskaite,Teng Fei,Maria Bromberg,Patxi San Martin-Uriz,Juan Roberto Rodriguez-Madoz,Kai Ziegler-Martin,Nazdar Adil-Gholam,Pascal Benz,Phuc Tran Huu,Christoph Stein-Thoeringer,Michael Schmitt,Karin Kleigrewe,Fabian Freitag,Zeno Riester,Justus Weber,Kira Mangold,Hermann Einsele,Felipe Prosper,Wilfried Ellmeier,Dirk Busch,Alexander Visekruna,John Slingerland,Roni Shouval,Karsten Hiller,Marcel van den Brink,Patrick Pausch,Paola Neri,Michael Hudecek,Hendrik Poeck,Maik Luu
DOI: https://doi.org/10.1101/2024.08.19.608538
2024-09-13
Abstract:Emerging data have highlighted a correlation between microbiome composition and cancer immunotherapy outcome. While commensal bacteria and their metabolites are known to modulate the host environment, contradictory effects and a lack of mechanistic understanding impede the translation of microbiome-based therapies into the clinic. In this study, we demonstrate that abundance of the commensal metabolite pentanoate is predictive for survival of chimeric antigen receptor (CAR) T cell patients in two independent cohorts. Its implementation in the CAR T cell manufacturing workflow overcomes solid tumor microenvironments in immunocompetent cancer models by hijacking the epigenetic-metabolic crosstalk, reducing exhaustion and promoting naive-like differentiation. While synergy of clinically relevant drugs mimicked the phenotype of pentanoate-engineered CAR T cells in vitro, in vivo challenge showed inferior tumor control. Metabolic tracing of 13C-pentanoate revealed citrate generation in the TCA cycle via the acetyl- and succinyl-CoA entry points as a unique feature of the C5 aliphatic chain. Inhibition of the ATP-citrate lyase, which links metabolic output and histone acetylation, led to accumulation of pentanoate-derived citrate from the succinyl-CoA route and decreased functionality of SCFA-engineered CAR T cells. Our data demonstrate that microbial metabolites are incorporated as epigenetic imprints and implementation into CAR T cell production might serve as embodiment of the microbiome-host axis benefits for clinical applications.
Immunology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is how to enhance the anti - tumor immune response through CAR - T cell engineering guided by microbial metabolites. Specifically, the researchers discovered a significant correlation between a microbial metabolite named pentanoate and the progression - free survival (PFS) of patients receiving CAR - T cell therapy. Based on this finding, the research team developed a new CAR - T cell manufacturing process. By adding pentanoate during the CAR - T cell production process, it is possible to overcome the unfavorable factors in the solid tumor microenvironment, improve the functionality and metabolic adaptability of CAR - T cells, and promote their differentiation into a naïve - like state. In addition, the study also explored how pentanoate affects the function of CAR - T cells through the epigenetic - metabolic interaction mechanism, and whether this effect can be simulated by existing clinical drugs. The main objectives of the study are: 1. **Reveal the relationship between pentanoate and the therapeutic effect of CAR - T cells**: By analyzing patient samples, the researchers found that patients with higher pentanoate levels showed better PFS and overall survival (OS) after receiving CAR - T cell therapy. 2. **Develop a new CAR - T cell manufacturing process**: The research team designed a new manufacturing process, adding pentanoate during the CAR - T cell production process to improve the functionality and metabolic adaptability of CAR - T cells. 3. **Explore the mechanism of action of pentanoate**: Through metabolic tracing experiments, the researchers found that pentanoate enters the tricarboxylic acid cycle (TCA cycle) through a unique pathway and participates in histone acetylation through the ATP - citrate lyase (ACLY) - mediated pathway, thereby affecting the epigenetic state of CAR - T cells. 4. **Evaluate the substitution effect of existing drugs**: The research team attempted to use existing HDAC inhibitors and metabolic regulators (such as mocetinostat and dichloroacetate) to simulate the effect of pentanoate, but found that these drugs could not fully reproduce the enhancement of CAR - T cell function by pentanoate. In conclusion, this paper aims to optimize the CAR - T cell manufacturing process through the introduction of the microbial metabolite pentanoate, thereby improving its efficacy in the treatment of solid tumors.